Trialect

Active

Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)

National Institutes of Health

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) proposes and will support the Cancer Prevention Clinical Trials Network (CP-CTNet) sites, for which the goals are as follows:

Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials;
Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints.
Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.

CP-CTNet consists of two types of components:

CP-CTNet Sites; and
One CP-CTNet Data Management, Auditing, and Statistical Center (DMASC) (covered by companion NOFO, RFA-CA-24-025 )

The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as in the management and analysis of the data.

Only one application per institution is allowed; the institutional resources needed to be a successful LAO and to avoid local competition for resources are too great for any one institution to be able to support more than one LAO. Interested applicants from within Duke should contact fundopps@duke.edu as early as possible.

Deadlines:

Letter of Intent: August 23, 2024
Application: Oct. 31, 2024

RFA-CA-24-024 Expiration Date November 01, 2024

Specialties

Medical

Medical - Clinical Science

Eligibility Requirements

The individual designated as PD/PI for the CP-CTNet Site must have his/her primary affiliation at the application-submitting institution (i.e., the LAO). For proposals with Multiple PDs/PIs, the second individual designated as MPI may have a primary affiliation at a different US institution.

These individuals are expected to be nationally and internationally recognized leaders in clinical trials of cancer preventive agents. This expertise should reflect mainly clinical trials of preventive agents (e.g., drugs, small molecules, vaccines/biologics) using measures of drug action and efficacy that include modulation of cancer-related biomarkers.

Additional expertise in other cancer preventive approaches (including medical devices, cancer preventive surgery, risk-reducing surgery, and non-surgical ablative techniques) is also desirable.

The PDs/PIs of applications submitted in response to this NOFO must not be named as Senior/Key Personnel or Other Significant Contributors on the CP-CTNet DMASC award supported under RFA-CA-24-025 .